Top

Current Obesity Reports

Published in:

Open Access 01-09-2020 | Obesity | Metabolism (M Dalamaga, Section Editor)

Omics Biomarkers in Obesity: Novel Etiological Insights and Targets for Precision Prevention

Authors: Krasimira Aleksandrova, Caue Egea Rodrigues, Anna Floegel, Wolfgang Ahrens

Published in: Current Obesity Reports | Issue 3/2020

Abstract

Purpose of Review

Omics-based technologies were suggested to provide an advanced understanding of obesity etiology and its metabolic consequences. This review highlights the recent developments in “omics”-based research aimed to identify obesity-related biomarkers.

Recent Findings

Recent advances in obesity and metabolism research increasingly rely on new technologies to identify mechanisms in the development of obesity using various “omics” platforms. Genetic and epigenetic biomarkers that translate into changes in transcriptome, proteome, and metabolome could serve as targets for obesity prevention. Despite a number of promising candidate biomarkers, there is an increased demand for larger prospective cohort studies to validate findings and determine biomarker reproducibility before they can find applications in primary care and public health.

Summary

“Omics” biomarkers have advanced our knowledge on the etiology of obesity and its links with chronic diseases. They bring substantial promise in identifying effective public health strategies that pave the way towards patient stratification and precision prevention.

Arroyo-Johnson C, Mincey KD. Obesity epidemiology worldwide. Gastroenterol Clin N Am. 2016;45(4):571–9. https://doi.org/10.1016/j.gtc.2016.07.012.CrossRef

Collaboration NCDRF. Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. Lancet. 2016;387(10026):1377–96. https://doi.org/10.1016/S0140-6736(16)30054-X.CrossRef

https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight WFsOaoUMO.

Williamson K, Nimegeer A, Lean M. Rising prevalence of BMI >/=40 kg/m(2): a high-demand epidemic needing better documentation. Obes Rev. 2020;21(4):e12986. https://doi.org/10.1111/obr.12986.CrossRefPubMedPubMedCentral

Jastreboff AM, Kotz CM, Kahan S, Kelly AS, Heymsfield SB. Obesity as a disease: the obesity society 2018 position statement. Obesity (Silver Spring). 2019;27(1):7–9. https://doi.org/10.1002/oby.22378.CrossRef

Abdelaal M, le Roux CW, Docherty NG. Morbidity and mortality associated with obesity. Ann Transl Med. 2017;5(7):161. doi: https://doi.org/10.21037/atm.2017.03.107.

Berry EM. The obesity pandemic-whose responsibility? No blame, no shame, not more of the same Front Nutr 2020;7:2. doi: https://doi.org/10.3389/fnut.2020.00002.

Bluher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019;15(5):288–98. https://doi.org/10.1038/s41574-019-0176-8.CrossRefPubMed

Martorell-Marugan J, Tabik S, Benhammou Y, del Val C, Zwir I, Herrera F, et al. Deep learning in omics data analysis and precision medicine. In: Husi H, editor. Computational biology. Brisbane (AU)2019.

10.

Ikram MA. Molecular pathological epidemiology: the role of epidemiology in the omics-era. Eur J Epidemiol. 2015;30(10):1077–8. https://doi.org/10.1007/s10654-015-0093-7.CrossRefPubMedPubMedCentral

11.

Aleksandrova K, Mozaffarian D, Pischon T. Addressing the perfect storm: biomarkers in obesity and pathophysiology of cardiometabolic risk. Clin Chem. 2018;64(1):142–53. https://doi.org/10.1373/clinchem.2017.275172.CrossRefPubMed

12.

Ordovas Munoz JM. Predictors of obesity: the “power” of the omics. Nutr Hosp 2013;28 Suppl 5:63–71. doi: https://doi.org/10.3305/nh.2013.28.sup5.6919.

13.

Misra BB, Langefeld CD, Olivier M, Cox LA. Integrated omics: tools, advances, and future approaches. J Mol Endocrinol. 2018:R21–45. https://doi.org/10.1530/JME-18-0055.

14.

Silventoinen K, Konttinen H. Obesity and eating behavior from the perspective of twin and genetic research. Neurosci Biobehav Rev. 2020;109:150–65. https://doi.org/10.1016/j.neubiorev.2019.12.012.CrossRefPubMed

15.

Pigeyre M, Yazdi FT, Kaur Y, Meyre D. Recent progress in genetics, epigenetics and metagenomics unveils the pathophysiology of human obesity. Clin Sci (Lond). 2016;130(12):943–86. https://doi.org/10.1042/CS20160136.CrossRef

16.

Stryjecki C, Alyass A, Meyre D. Ethnic and population differences in the genetic predisposition to human obesity. Obes Rev. 2018;19(1):62–80. https://doi.org/10.1111/obr.12604.CrossRefPubMed

17.

Loos RJF, Janssens A. Predicting polygenic obesity using genetic information. Cell Metab. 2017;25(3):535–43. https://doi.org/10.1016/j.cmet.2017.02.013.CrossRefPubMed

18.

Manzoni C, Kia DA, Vandrovcova J, Hardy J, Wood NW, Lewis PA, et al. Genome, transcriptome and proteome: the rise of omics data and their integration in biomedical sciences. Brief Bioinform. 2018;19(2):286–302. https://doi.org/10.1093/bib/bbw114.CrossRefPubMed

19.

Torkamani A, Topol E. Polygenic risk scores expand to obesity. Cell. 2019;177(3):518–20. https://doi.org/10.1016/j.cell.2019.03.051.CrossRefPubMed

20.

Fang J, Gong C, Wan Y, Xu Y, Tao F, Sun Y. Polygenic risk, adherence to a healthy lifestyle, and childhood obesity. Pediatr Obes. 2019;14(4):e12489. https://doi.org/10.1111/ijpo.12489.CrossRefPubMed

21.

Abadi A, Alyass A, Robiou du Pont S, Bolker B, Singh P, Mohan V, et al. Penetrance of polygenic obesity susceptibility loci across the body mass index distribution. Am J Hum Genet. 2017;101(6):925–38. https://doi.org/10.1016/j.ajhg.2017.10.007.CrossRefPubMedPubMedCentral

22.

Yengo L, Sidorenko J, Kemper KE, Zheng Z, Wood AR, Weedon MN, et al. Meta-analysis of genome-wide association studies for height and body mass index in approximately 700000 individuals of European ancestry. Hum Mol Genet. 2018;27(20):3641–9. https://doi.org/10.1093/hmg/ddy271.CrossRefPubMedPubMedCentral

23.

Goodarzi MO. Genetics of obesity: what genetic association studies have taught us about the biology of obesity and its complications. Lancet Diabetes Endocrinol. 2018;6(3):223–36. https://doi.org/10.1016/S2213-8587(17)30200-0.CrossRefPubMed

24.

Fu J, Hofker M, Wijmenga C. Apple or pear: size and shape matter. Cell Metab. 2015;21(4):507–8. https://doi.org/10.1016/j.cmet.2015.03.016.CrossRefPubMed

25.

Khera AV, Chaffin M, Wade KH, Zahid S, Brancale J, Xia R, et al. Polygenic prediction of weight and obesity trajectories from birth to adulthood. Cell. 2019;177(3):587–96 e9. https://doi.org/10.1016/j.cell.2019.03.028.CrossRefPubMedPubMedCentral

26.

Tyrrell J, Wood AR, Ames RM, Yaghootkar H, Beaumont RN, Jones SE, et al. Gene-obesogenic environment interactions in the UK Biobank study. Int J Epidemiol. 2017;46(2):559–75. https://doi.org/10.1093/ije/dyw337.CrossRefPubMedPubMedCentral

27.

Murr R. Interplay between different epigenetic modifications and mechanisms. Adv Genet. 2010;70:101–41. https://doi.org/10.1016/B978-0-12-380866-0.60005-8.CrossRefPubMed

28.

Cazaly E, Saad J, Wang W, Heckman C, Ollikainen M, Tang J. Making sense of the epigenome using data integration approaches. Front Pharmacol. 2019;10:126. https://doi.org/10.3389/fphar.2019.00126.CrossRefPubMedPubMedCentral

29.

Skinner MK. Environmental epigenomics and disease susceptibility. EMBO Rep. 2011;12(7):620–2. https://doi.org/10.1038/embor.2011.125.CrossRefPubMedPubMedCentral

30.

Fransen HP, Peeters PH, Beulens JW, Boer JM, de Wit GA, Onland-Moret NC, et al. Exposure to famine at a young age and unhealthy lifestyle behavior later in life. PLoS One. 2016;11(5):e0156609. https://doi.org/10.1371/journal.pone.0156609.CrossRefPubMedPubMedCentral

31.

Zhou J, Zhang L, Xuan P, Fan Y, Yang L, Hu C, et al. The relationship between famine exposure during early life and body mass index in adulthood: a systematic review and meta-analysis. PLoS One. 2018;13(2):e0192212. https://doi.org/10.1371/journal.pone.0192212.CrossRefPubMedPubMedCentral

32.

Tobi EW, Slieker RC, Stein AD, Suchiman HE, Slagboom PE, van Zwet EW, et al. Early gestation as the critical time-window for changes in the prenatal environment to affect the adult human blood methylome. Int J Epidemiol. 2015;44(4):1211–23. https://doi.org/10.1093/ije/dyv043.CrossRefPubMedPubMedCentral

33.

Kaushik P, Anderson JT. Obesity: epigenetic aspects. Biomol Concepts. 2016;7(3):145–55. https://doi.org/10.1515/bmc-2016-0010.CrossRefPubMed

34.

Heijmans BT, Tobi EW, Stein AD, Putter H, Blauw GJ, Susser ES, et al. Persistent epigenetic differences associated with prenatal exposure to famine in humans. Proc Natl Acad Sci U S A. 2008;105(44):17046–9. https://doi.org/10.1073/pnas.0806560105.CrossRefPubMedPubMedCentral

35.

Tobi EW, Slieker RC, Luijk R, Dekkers KF, Stein AD, Xu KM, et al. DNA methylation as a mediator of the association between prenatal adversity and risk factors for metabolic disease in adulthood. Sci Adv. 2018;4(1):eaao4364. doi: https://doi.org/10.1126/sciadv.aao4364.

36.

Wahl S, Drong A, Lehne B, Loh M, Scott WR, Kunze S, et al. Epigenome-wide association study of body mass index, and the adverse outcomes of adiposity. Nature. 2017;541(7635):81–6. https://doi.org/10.1038/nature20784.CrossRefPubMed

37.

Sayols-Baixeras S, Subirana I, Fernandez-Sanles A, Senti M, Lluis-Ganella C, Marrugat J, et al. DNA methylation and obesity traits: an epigenome-wide association study. The REGICOR study Epigenetics. 2017;12(10):909–16. https://doi.org/10.1080/15592294.2017.1363951.CrossRefPubMed

38.

Ling C, Ronn T. Epigenetics in human obesity and type 2 diabetes. Cell Metab. 2019;29(5):1028–44. https://doi.org/10.1016/j.cmet.2019.03.009.CrossRefPubMedPubMedCentral

39.

Loh M, Zhou L, Ng HK, Chambers JC. Epigenetic disturbances in obesity and diabetes: epidemiological and functional insights. Mol Metab. 2019;27S:S33–41. https://doi.org/10.1016/j.molmet.2019.06.011.CrossRefPubMed

40.

Lafortuna CL, Tovar AR, Rastelli F, Tabozzi SA, Caramenti M, Orozco-Ruiz X, et al. Clinical, functional, behavioural and epigenomic biomarkers of obesity. Front Biosci (Landmark Ed). 2017;22:1655–81. doi: https://doi.org/10.2741/4564.

41.

Castellano-Castillo D, Denechaud PD, Fajas L, Moreno-Indias I, Oliva-Olivera W, Tinahones F, et al. Human adipose tissue H3K4me3 histone mark in adipogenic, lipid metabolism and inflammatory genes is positively associated with BMI and HOMA-IR. PLoS One. 2019;14(4):e0215083. https://doi.org/10.1371/journal.pone.0215083.CrossRefPubMedPubMedCentral

42.

Carter AC, Chang HY, Church G, Dombkowski A, Ecker JR, Gil E, et al. Challenges and recommendations for epigenomics in precision health. Nat Biotechnol. 2017;35(12):1128–32. https://doi.org/10.1038/nbt.4030.CrossRefPubMedPubMedCentral

43.

Lafave LM, Levine RL. Mining the epigenetic landscape in ALL. Nat Genet. 2013;45(11):1269–70. https://doi.org/10.1038/ng.2808.CrossRefPubMed

44.

Thomou T, Mori MA, Dreyfuss JM, Konishi M, Sakaguchi M, Wolfrum C, et al. Adipose-derived circulating miRNAs regulate gene expression in other tissues. Nature. 2017;542(7642):450–5. https://doi.org/10.1038/nature21365.CrossRefPubMedPubMedCentral

45.

Reuter JA, Spacek DV, Snyder MP. High-throughput sequencing technologies. Mol Cell. 2015;58(4):586–97. https://doi.org/10.1016/j.molcel.2015.05.004.CrossRefPubMedPubMedCentral

46.

Homuth G, Wahl S, Muller C, Schurmann C, Mader U, Blankenberg S, et al. Extensive alterations of the whole-blood transcriptome are associated with body mass index: results of an mRNA profiling study involving two large population-based cohorts. BMC Med Genet. 2015;8:65. https://doi.org/10.1186/s12920-015-0141-x.CrossRef

47.

Ghosh S, Dent R, Harper ME, Gorman SA, Stuart JS, McPherson R. Gene expression profiling in whole blood identifies distinct biological pathways associated with obesity. BMC Med Genet. 2010;3:56. https://doi.org/10.1186/1755-8794-3-56.CrossRef

48.

Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature. 2009;458(7235):223–7. https://doi.org/10.1038/nature07672.CrossRefPubMedPubMedCentral

49.

Ortega FJ, Moreno-Navarrete JM, Pardo G, Sabater M, Hummel M, Ferrer A, et al. MiRNA expression profile of human subcutaneous adipose and during adipocyte differentiation. PLoS One. 2010;5(2):e9022. https://doi.org/10.1371/journal.pone.0009022.CrossRefPubMedPubMedCentral

50.

Iacomino G, Siani A. Role of microRNAs in obesity and obesity-related diseases. Genes Nutr. 2017;12:23. https://doi.org/10.1186/s12263-017-0577-z.CrossRefPubMedPubMedCentral

51.

Landrier JF, Derghal A, Mounien L. MicroRNAs in obesity and related metabolic disorders. Cells. 2019;8(8). doi: https://doi.org/10.3390/cells8080859.

52.

Del Corno M, Baldassarre A, Calura E, Conti L, Martini P, Romualdi C, et al. Transcriptome profiles of human visceral adipocytes in obesity and colorectal cancer unravel the effects of body mass index and polyunsaturated fatty acids on genes and biological processes related to tumorigenesis. Front Immunol. 2019;10:265. https://doi.org/10.3389/fimmu.2019.00265.CrossRefPubMedPubMedCentral

53.

Klimcakova E, Roussel B, Marquez-Quinones A, Kovacova Z, Kovacikova M, Combes M, et al. Worsening of obesity and metabolic status yields similar molecular adaptations in human subcutaneous and visceral adipose tissue: decreased metabolism and increased immune response. J Clin Endocrinol Metab. 2011;96(1):E73–82. https://doi.org/10.1210/jc.2010-1575.CrossRefPubMed

54.

Ji C, Guo X. The clinical potential of circulating microRNAs in obesity. Nat Rev Endocrinol. 2019;15(12):731–43. https://doi.org/10.1038/s41574-019-0260-0.CrossRefPubMed

55.

Ortiz-Dosal A, Rodil-Garcia P, Salazar-Olivo LA. Circulating microRNAs in human obesity: a systematic review. Biomarkers. 2019;24(6):499–509. https://doi.org/10.1080/1354750X.2019.1606279.CrossRefPubMed

56.

Sun L, Goff LA, Trapnell C, Alexander R, Lo KA, Hacisuleyman E, et al. Long noncoding RNAs regulate adipogenesis. Proc Natl Acad Sci U S A. 2013;110(9):3387–92. https://doi.org/10.1073/pnas.1222643110.CrossRefPubMedPubMedCentral

57.

Zhao XY, Lin JD. Long noncoding RNAs: a new regulatory code in metabolic control. Trends Biochem Sci. 2015;40(10):586–96. https://doi.org/10.1016/j.tibs.2015.08.002.CrossRefPubMedPubMedCentral

58.

Alexander M, O’Connell RM. Noncoding RNAs and chronic inflammation: micro-managing the fire within. Bioessays. 2015;37(9):1005–15. https://doi.org/10.1002/bies.201500054.CrossRefPubMedPubMedCentral

59.

Sun M, Kraus WL. From discovery to function: the expanding roles of long noncoding RNAs in physiology and disease. Endocr Rev. 2015;36(1):25–64. https://doi.org/10.1210/er.2014-1034.CrossRefPubMed

60.

Wei S, Du M, Jiang Z, Hausman GJ, Zhang L, Dodson MV. Long noncoding RNAs in regulating adipogenesis: new RNAs shed lights on obesity. Cell Mol Life Sci. 2016;73(10):2079–87. https://doi.org/10.1007/s00018-016-2169-2.CrossRefPubMedPubMedCentral

61.

Di Ruscio A, Ebralidze AK, Benoukraf T, Amabile G, Goff LA, Terragni J, et al. DNMT1-interacting RNAs block gene-specific DNA methylation. Nature. 2013;503(7476):371–6. https://doi.org/10.1038/nature12598.CrossRefPubMedPubMedCentral

62.

Kukurba KR, Montgomery SB. RNA sequencing and analysis. Cold Spring Harb Protoc. 2015;2015(11):951–69. https://doi.org/10.1101/pdb.top084970.CrossRefPubMedPubMedCentral

63.

Masood A, Benabdelkamel H, Alfadda AA. Obesity proteomics: an update on the strategies and tools employed in the study of human obesity. High Throughput. 2018;7(3). doi: https://doi.org/10.3390/ht7030027.

64.

Pardo M, Roca-Rivada A, Seoane LM, Casanueva FF. Obesidomics: contribution of adipose tissue secretome analysis to obesity research. Endocrine. 2012;41(3):374–83. https://doi.org/10.1007/s12020-012-9617-z.CrossRefPubMed

65.

Geyer PE, Wewer Albrechtsen NJ, Tyanova S, Grassl N, Iepsen EW, Lundgren J, et al. Proteomics reveals the effects of sustained weight loss on the human plasma proteome. Mol Syst Biol. 2016;12(12):901. doi: https://doi.org/10.15252/msb.20167357.

66.

Sahebekhtiari N, Saraswat M, Joenvaara S, Jokinen R, Lovric A, Kaye S, et al. Plasma proteomics analysis reveals dysregulation of complement proteins and inflammation in acquired obesity-a study on rare BMI-discordant monozygotic twin pairs. Proteomics Clin Appl. 2019;13(4):e1800173. https://doi.org/10.1002/prca.201800173.CrossRefPubMed

67.

Garrison CB, Lastwika KJ, Zhang Y, Li CI, Lampe PD. Proteomic analysis, immune dysregulation, and pathway interconnections with obesity. J Proteome Res. 2017;16(1):274–87. https://doi.org/10.1021/acs.jproteome.6b00611.CrossRefPubMed

68.

Al-Daghri NM, Manousopoulou A, Alokail MS, Yakout S, Alenad A, Garay-Baquero DJ, et al. Sex-specific correlation of IGFBP-2 and IGFBP-3 with vitamin D status in adults with obesity: a cross-sectional serum proteomics study. Nutr Diabetes. 2018;8(1):54. https://doi.org/10.1038/s41387-018-0063-8.CrossRefPubMedPubMedCentral

69.

Doumatey AP, Zhou J, Zhou M, Prieto D, Rotimi CN, Adeyemo A. Proinflammatory and lipid biomarkers mediate metabolically healthy obesity: a proteomics study. Obesity (Silver Spring). 2016;24(6):1257–65. https://doi.org/10.1002/oby.21482.CrossRef

70.

Cominetti O, Nunez Galindo A, Corthesy J, Valsesia A, Irincheeva I, Kussmann M, et al. Obesity shows preserved plasma proteome in large independent clinical cohorts. Sci Rep. 2018;8(1):16981. https://doi.org/10.1038/s41598-018-35321-7.CrossRefPubMedPubMedCentral

71.

Griffiths WJ, Koal T, Wang Y, Kohl M, Enot DP, Deigner HP. Targeted metabolomics for biomarker discovery. Angew Chem Int Ed Engl. 2010;49(32):5426–45. https://doi.org/10.1002/anie.200905579.CrossRefPubMed

72.

Dettmer K, Aronov PA, Hammock BD. Mass spectrometry-based metabolomics. Mass Spectrom Rev. 2007;26(1):51–78. https://doi.org/10.1002/mas.20108.CrossRefPubMedPubMedCentral

73.

Rangel-Huerta OD, Pastor-Villaescusa B, Gil A. Are we close to defining a metabolomic signature of human obesity? A systematic review of metabolomics studies. Metabolomics. 2019;15(6):93. https://doi.org/10.1007/s11306-019-1553-y.CrossRefPubMedPubMedCentral

74.

Floegel A, Wientzek A, Bachlechner U, Jacobs S, Drogan D, Prehn C, et al. Linking diet, physical activity, cardiorespiratory fitness and obesity to serum metabolite networks: findings from a population-based study. Int J Obes. 2014;38(11):1388–96. https://doi.org/10.1038/ijo.2014.39.CrossRef

75.

Marco-Ramell A, Tulipani S, Palau-Rodriguez M, Gonzalez-Dominguez R, Minarro A, Jauregui O, et al. Untargeted profiling of concordant/discordant phenotypes of high insulin resistance and obesity to predict the risk of developing diabetes. J Proteome Res. 2018;17(7):2307–17. https://doi.org/10.1021/acs.jproteome.7b00855.CrossRefPubMed

76.

Tulipani S, Palau-Rodriguez M, Minarro Alonso A, Cardona F, Marco-Ramell A, Zonja B, et al. Biomarkers of morbid obesity and prediabetes by metabolomic profiling of human discordant phenotypes. Clin Chim Acta. 2016;463:53–61. https://doi.org/10.1016/j.cca.2016.10.005.CrossRefPubMed

77.

Gannon NP, Schnuck JK, Vaughan RA. BCAA metabolism and insulin sensitivity - dysregulated by metabolic status? Mol Nutr Food Res. 2018;62(6):e1700756. https://doi.org/10.1002/mnfr.201700756.CrossRefPubMed

78.

Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, et al. Metabolite profiles and the risk of developing diabetes. Nat Med. 2011;17(4):448–53. https://doi.org/10.1038/nm.2307.CrossRefPubMedPubMedCentral

79.

Floegel A, Stefan N, Yu Z, Muhlenbruch K, Drogan D, Joost HG, et al. Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes. 2013;62(2):639–48. https://doi.org/10.2337/db12-0495.CrossRefPubMedPubMedCentral

80.

Siddik MAB, Shin AC. Recent progress on branched-Chain amino acids in obesity, diabetes, and beyond. Endocrinol Metab (Seoul). 2019;34(3):234–46. https://doi.org/10.3803/EnM.2019.34.3.234.CrossRef

81.

Wishart DS. Emerging applications of metabolomics in drug discovery and precision medicine. Nat Rev Drug Discov. 2016;15(7):473–84. https://doi.org/10.1038/nrd.2016.32.CrossRefPubMed

82.

Quehenberger O, Armando AM, Brown AH, Milne SB, Myers DS, Merrill AH, et al. Lipidomics reveals a remarkable diversity of lipids in human plasma. J Lipid Res. 2010;51(11):3299–305. https://doi.org/10.1194/jlr.M009449.CrossRefPubMedPubMedCentral

83.

Wenk MR. Lipidomics: new tools and applications. Cell. 2010;143(6):888–95. https://doi.org/10.1016/j.cell.2010.11.033.CrossRefPubMed

84.

Yang K, Han X. Lipidomics: techniques, applications, and outcomes related to biomedical sciences. Trends Biochem Sci. 2016;41(11):954–69. https://doi.org/10.1016/j.tibs.2016.08.010.CrossRefPubMedPubMedCentral

85.

Klop B, Elte JW, Cabezas MC. Dyslipidemia in obesity: mechanisms and potential targets. Nutrients. 2013;5(4):1218–40. https://doi.org/10.3390/nu5041218.CrossRefPubMedPubMedCentral

86.

Mousa A, Naderpoor N, Mellett N, Wilson K, Plebanski M, Meikle PJ, et al. Lipidomic profiling reveals early-stage metabolic dysfunction in overweight or obese humans. Biochim Biophys Acta Mol Cell Biol Lipids. 2019;1864(3):335–43. https://doi.org/10.1016/j.bbalip.2018.12.014.CrossRefPubMed

87.

Piening BD, Zhou W, Contrepois K, Rost H, Gu Urban GJ, Mishra T, et al. Integrative personal omics profiles during periods of weight gain and loss. Cell Syst 2018;6(2):157–170 e8. doi: https://doi.org/10.1016/j.cels.2017.12.013.

88.

Cole LK, Vance JE, Vance DE. Phosphatidylcholine biosynthesis and lipoprotein metabolism. Biochim Biophys Acta. 2012;1821(5):754–61. https://doi.org/10.1016/j.bbalip.2011.09.009.CrossRefPubMed

89.

Kim MJ, Yang HJ, Kim JH, Ahn CW, Lee JH, Kim KS, et al. Obesity-related metabolomic analysis of human subjects in black soybean peptide intervention study by ultraperformance liquid chromatography and quadrupole-time-of-flight mass spectrometry. J Obes. 2013;2013:874981–11. https://doi.org/10.1155/2013/874981.CrossRefPubMedPubMedCentral

90.

Bertozzi CR, Rabuka D. Structural basis of glycan diversity. In: nd, Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, et al., editors. Essentials of glycobiology. Cold Spring Harbor (NY)2009.

91.

Cao WQ, Liu MQ, Kong SY, Wu MX, Huang ZZ, Yang PY. Novel methods in glycomics: a 2019 update. Expert Rev Proteomics. 2020;17(1):11–25. https://doi.org/10.1080/14789450.2020.1708199.CrossRefPubMed

92.

Everest-Dass AV, Moh ESX, Ashwood C, Shathili AMM, Packer NH. Human disease glycomics: technology advances enabling protein glycosylation analysis - part 1. Expert Rev Proteomics. 2018;15(2):165–82. https://doi.org/10.1080/14789450.2018.1421946.CrossRefPubMed

93.

Rudman N, Gornik O, Lauc G. Altered N-glycosylation profiles as potential biomarkers and drug targets in diabetes. FEBS Lett. 2019;593(13):1598–615. https://doi.org/10.1002/1873-3468.13495.CrossRefPubMed

94.

Rudd P, Karlsson NG, Khoo KH, Packer NH. Glycomics and glycoproteomics. In: rd, Varki A, Cummings RD, Esko JD, Stanley P, Hart GW, et al., editors. Essentials of glycobiology. Cold Spring Harbor (NY)2015. p. 653–66.

95.

Adua E, Russell A, Roberts P, Wang Y, Song M, Wang W. Innovation analysis on postgenomic biomarkers: glycomics for chronic diseases. OMICS. 2017;21(4):183–96. https://doi.org/10.1089/omi.2017.0035.CrossRefPubMed

96.

Kristic J, Vuckovic F, Menni C, Klaric L, Keser T, Beceheli I, et al. Glycans are a novel biomarker of chronological and biological ages. J Gerontol A Biol Sci Med Sci. 2014;69(7):779–89. https://doi.org/10.1093/gerona/glt190.CrossRefPubMed

97.

Liu D, Li Q, Dong J, Li D, Xu X, Xing W, et al. The association between normal BMI with central adiposity and proinflammatory potential immunoglobulin G N-glycosylation. Diabetes Metab Syndr Obes. 2019;12:2373–85. https://doi.org/10.2147/DMSO.S216318.CrossRefPubMedPubMedCentral

98.

Nikolac Perkovic M, Pucic Bakovic M, Kristic J, Novokmet M, Huffman JE, Vitart V, et al. The association between galactosylation of immunoglobulin G and body mass index. Prog Neuro-Psychopharmacol Biol Psychiatry. 2014;48:20–5. https://doi.org/10.1016/j.pnpbp.2013.08.014.CrossRef

99.

Russell AC, Kepka A, Trbojevic-Akmacic I, Ugrina I, Song M, Hui J, et al. Increased central adiposity is associated with pro-inflammatory immunoglobulin G N-glycans. Immunobiology. 2019;224(1):110–5. https://doi.org/10.1016/j.imbio.2018.10.002.CrossRefPubMed

100.

Young VB. The role of the microbiome in human health and disease: an introduction for clinicians. BMJ. 2017;356:j831. https://doi.org/10.1136/bmj.j831.CrossRefPubMed

101.

Plotnikoff GA, Riley D. The human microbiome. Glob Adv Health Med. 2014;3(3):4–5. https://doi.org/10.7453/gahmj.2014.023.CrossRefPubMedPubMedCentral

102.

Wilkins LJ, Monga M, Miller AW. Defining dysbiosis for a cluster of chronic diseases. Sci Rep. 2019;9(1):12918. https://doi.org/10.1038/s41598-019-49452-y.CrossRefPubMedPubMedCentral

103.

Song EJ, Lee ES, Nam YD. Progress of analytical tools and techniques for human gut microbiome research. J Microbiol. 2018;56(10):693–705. https://doi.org/10.1007/s12275-018-8238-5.CrossRefPubMed

104.

Shakya M, Lo CC, Chain PSG. Advances and challenges in metatranscriptomic analysis. Front Genet. 2019;10:904. https://doi.org/10.3389/fgene.2019.00904.CrossRefPubMedPubMedCentral

105.

Lin H, He QY, Shi L, Sleeman M, Baker MS, Nice EC. Proteomics and the microbiome: pitfalls and potential. Expert Rev Proteomics. 2019;16(6):501–11. https://doi.org/10.1080/14789450.2018.1523724.CrossRefPubMed

106.

Chen MX, Wang SY, Kuo CH, Tsai IL. Metabolome analysis for investigating host-gut microbiota interactions. J Formos Med Assoc. 2019;118(Suppl 1):S10–22. https://doi.org/10.1016/j.jfma.2018.09.007.CrossRefPubMed

107.

John GK, Mullin GE. The gut microbiome and obesity. Curr Oncol Rep. 2016;18(7):45. https://doi.org/10.1007/s11912-016-0528-7.CrossRefPubMed

108.

Musso G, Gambino R, Cassader M. Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes. Annu Rev Med. 2011;62:361–80. https://doi.org/10.1146/annurev-med-012510-175505.CrossRefPubMed

109.

Delzenne NM, Cani PD. Interaction between obesity and the gut microbiota: relevance in nutrition. Annu Rev Nutr. 2011;31:15–31. https://doi.org/10.1146/annurev-nutr-072610-145146.CrossRefPubMed

110.

Sze MA, Schloss PD. Looking for a signal in the noise: revisiting obesity and the microbiome. mBio. 2016;7(4). doi: https://doi.org/10.1128/mBio.01018-16.

111.

Walters WA, Xu Z, Knight R. Meta-analyses of human gut microbes associated with obesity and IBD. FEBS Lett. 2014;588(22):4223–33. https://doi.org/10.1016/j.febslet.2014.09.039.CrossRefPubMedPubMedCentral

112.

Armour CR, Nayfach S, Pollard KS, Sharpton TJ. A metagenomic meta-analysis reveals functional signatures of health and disease in the human gut microbiome. mSystems. 2019;4(4). doi: https://doi.org/10.1128/mSystems.00332-18.

113.

Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes. 2016;7(3):189–200. https://doi.org/10.1080/19490976.2015.1134082.CrossRefPubMedPubMedCentral

114.

Chambers ES, Preston T, Frost G, Morrison DJ. Role of gut microbiota-generated short-chain fatty acids in metabolic and cardiovascular health. Curr Nutr Rep. 2018;7(4):198–206. https://doi.org/10.1007/s13668-018-0248-8.CrossRefPubMedPubMedCentral

115.

Cox LM, Blaser MJ. Antibiotics in early life and obesity. Nat Rev Endocrinol. 2015;11(3):182–90. https://doi.org/10.1038/nrendo.2014.210.CrossRefPubMed

116.

Block JP, Bailey LC, Gillman MW, Lunsford D, Daley MF, Eneli I, et al. Early antibiotic exposure and weight outcomes in young children. Pediatrics. 2018;142(6). doi: https://doi.org/10.1542/peds.2018-0290.

117.

Shao X, Ding X, Wang B, Li L, An X, Yao Q, et al. Antibiotic exposure in early life increases risk of childhood obesity: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2017;8:170. doi: https://doi.org/10.3389/fendo.2017.00170.

118.

Scott FI, Horton DB, Mamtani R, Haynes K, Goldberg DS, Lee DY, Lewis JD Administration of antibiotics to children before age 2 years increases risk for childhood obesity. Gastroenterology. 2016;151(1):120–129 e5. doi: https://doi.org/10.1053/j.gastro.2016.03.006.

119.

Ferrarese R, Ceresola ER, Preti A, Canducci F. Probiotics, prebiotics and synbiotics for weight loss and metabolic syndrome in the microbiome era. Eur Rev Med Pharmacol Sci. 2018;22(21):7588–605. doi: https://doi.org/10.26355/eurrev_201811_16301.

120.

Frame LA, Costa E, Jackson SA. Current explorations of nutrition and the gut microbiome: a comprehensive evaluation of the review literature. Nutr Rev. 2020. https://doi.org/10.1093/nutrit/nuz106.

121.

Poitou C, Perret C, Mathieu F, Truong V, Blum Y, Durand H, et al. Bariatric surgery induces disruption in inflammatory signaling pathways mediated by immune cells in adipose tissue: a RNA-Seq study. PLoS One. 2015;10(5):e0125718. https://doi.org/10.1371/journal.pone.0125718.CrossRefPubMedPubMedCentral

122.

Izquierdo AG, Crujeiras AB. Obesity-related epigenetic changes after bariatric surgery. Front Endocrinol (Lausanne). 2019;10:232. doi: https://doi.org/10.3389/fendo.2019.00232.

123.

Nicoletti CF, Pinhel MAS, Noronha NY, de Oliveira BA, Salgado Junior W, Jacome A, et al. Altered pathways in methylome and transcriptome longitudinal analysis of normal weight and bariatric surgery women. Sci Rep. 2020;10(1):6515. https://doi.org/10.1038/s41598-020-60814-9.CrossRefPubMedPubMedCentral

124.

van Dijk SJ, Molloy PL, Varinli H, Morrison JL, Muhlhausler BS, Members of Epi S. Epigenetics and human obesity. Int J Obes 2015;39(1):85–97. doi: https://doi.org/10.1038/ijo.2014.34.

125.

Gonzalez-Plaza JJ, Santiago-Fernandez C, Gutierrez-Repiso C, Garcia-Serrano S, Rodriguez-Pacheco F, Ho-Plagaro A, et al. The changes in the transcriptomic profiling of subcutaneous adipose tissue after bariatric surgery depend on the insulin resistance state. Surg Obes Relat Dis. 2018;14(8):1182–91. https://doi.org/10.1016/j.soard.2018.04.010.CrossRefPubMed

126.

Samczuk P, Ciborowski M, Kretowski A. Application of metabolomics to study effects of bariatric surgery. J Diabetes Res. 2018;2018:6270875–13. https://doi.org/10.1155/2018/6270875.CrossRefPubMedPubMedCentral

127.

Palau-Rodriguez M, Tulipani S, Marco-Ramell A, Minarro A, Jauregui O, Sanchez-Pla A, et al. Metabotypes of response to bariatric surgery independent of the magnitude of weight loss. PLoS One. 2018;13(6):e0198214. https://doi.org/10.1371/journal.pone.0198214.CrossRefPubMedPubMedCentral

128.

Perakakis N, Yazdani A, Karniadakis GE, Mantzoros C. Omics, big data and machine learning as tools to propel understanding of biological mechanisms and to discover novel diagnostics and therapeutics. Metabolism. 2018;87:A1–9. https://doi.org/10.1016/j.metabol.2018.08.002.CrossRefPubMedPubMedCentral

129.

Subramanian I, Verma S, Kumar S, Jere A, Anamika K. Multi-omics data integration, interpretation, and its application. Bioinform Biol Insights. 2020;14:1177932219899051. https://doi.org/10.1177/1177932219899051.CrossRefPubMedPubMedCentral

130.

Conesa A, Beck S. Making multi-omics data accessible to researchers. Sci Data. 2019;6(1):251. https://doi.org/10.1038/s41597-019-0258-4.CrossRefPubMedPubMedCentral

Title: Omics Biomarkers in Obesity: Novel Etiological Insights and Targets for Precision Prevention
Authors: Krasimira Aleksandrova
Caue Egea Rodrigues
Anna Floegel
Wolfgang Ahrens
Publication date: 01-09-2020
Publisher: Springer US
Keywords: Obesity
Obesity
Biomarkers
Published in: Current Obesity Reports / Issue 3/2020
Electronic ISSN: 2162-4968
DOI: https://doi.org/10.1007/s13679-020-00393-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 3/2020

From the Knife to the Endoscope—a History of Bariatric Surgery

Outcomes in Bariatric and Metabolic Surgery: an Updated 5-Year Review

From the Knife to the Endoscope—a History of Bariatric Surgery

Autoantibody Production in Obesity: Is There Evidence for a Link Between Obesity and Autoimmunity?

Protein-Rich Diets for Weight Loss Maintenance

The Retail Food Environment, Store Foods, and Diet and Health among Indigenous Populations: a Scoping Review

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage